Emergent Biosolutions
EBS
214 hedge funds and large institutions have $1.22B invested in Emergent Biosolutions in 2016 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 84 increasing their positions, 76 reducing their positions, and 23 closing their positions.
43% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 23
11% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 76
4% more funds holding
Funds holding: 205 → 214 (+9)
0.06% more ownership
Funds ownership: 85.03% → 85.1% (+0.06%)
6% less capital invested
Capital invested by funds: $1.29B → $1.22B (-$72.1M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
58% less call options, than puts
Call options by funds: $2.64M | Put options by funds: $6.25M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$23.8M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$14M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.8M |
| 4 |
TA
Teachers Advisors
New York
|
+$7.9M |
| 5 |
State Street
Boston,
Massachusetts
|
+$7.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$26.9M |
| 2 |
Bank of New York Mellon
New York
|
-$17.8M |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$8.94M |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$5.99M |
| 5 |
FMA
Fiduciary Management Associates
Chicago,
Illinois
|
-$5.52M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BRWA
226
B. Riley Wealth Advisors
Boca Raton,
Florida
| – | -$285K | -7,102 | Closed |
|
|
DIA
227
Denver Investment Advisors
Denver,
Colorado
| – | -$280K | -6,996 | Closed |
|
228
Stifel Financial
St. Louis,
Missouri
| – | -$248K | -6,189 | Closed |
|
229
Jane Street
New York
| – | -$231K | -5,770 | Closed |
|
|
PA
230
Profund Advisors
Bethesda,
Maryland
| – | -$222K | -5,548 | Closed |
|
231
ProShare Advisors
Bethesda,
Maryland
| – | -$207K | -5,173 | Closed |
|
|
IA
232
IFP Advisors
Tampa,
Florida
| – | -$21K | -519 | Closed |
|
|
TRCT
233
Tower Research Capital (TRC)
New York
| – | -$12K | -300 | Closed |
|
234
Simplex Trading
Chicago,
Illinois
| – | -$3.85K | -109 | Closed |
|
|
GAM
235
Gemmer Asset Management
Walnut Creek,
California
| – | -$1.13K | -32 | -58% |
|
|
KCPG
236
Kavar Capital Partners Group
Leawood,
Kansas
| – | -$1K | -25 | Closed |
|
EBS Hedge Fund Activity: Q1 2016 in Review
214 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q1 2016, worth a combined $1.22B — down 5.6% from $1.29B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new EBS positions and 23 closed out — a net gain of 10 holders — while 84 added to existing stakes and 76 trimmed.
The largest buyer was Acadian Asset Management, adding an estimated $23.8M. The largest seller was Broadfin Capital, exiting entirely with an estimated $26.9M sold.
- 214 institutional investors held Emergent Biosolutions (EBS) as of Q1 2016, up from 205 in Q4 2015.
- Funds reported $1.22B of Emergent Biosolutions stock for Q1 2016, down 5.6% quarter-over-quarter.
- 33 funds opened new Emergent Biosolutions positions in Q1 2016 and 23 closed out, a net change of +10 holders.
- The largest Emergent Biosolutions buyer in Q1 2016 was Acadian Asset Management, an estimated $23.8M added.
- The largest Emergent Biosolutions seller in Q1 2016 was Broadfin Capital, an estimated $26.9M sold.
Based on aggregated 13F filings for Q1 2016.